3.16 Pinguecula

Date of revision:

21/09/2026

Date of next review:

21/09/2026

Date of publication:

26/10/2026


Differential Diagnosis (1) 

  • Pterygium 

    • Distinguished by extension across the limbus onto the cornea 

    • A pinguecula does not involve the cornea and does not progress to a pterygium; the two are distinct conditions  

  • Ocular surface squamous neoplasia (particularly where a pinguecula is keratinised)  

  • Dermoid cyst  

  • Epithelial retention cyst (thin-walled lesion containing clear fluid) 

  • Bitot spot (associated with vitamin A deficiency)  

  • Inflammatory conditions including: 

    • Episcleritis 

    • Angular conjunctivitis 

    • Phlyctenular disease  


Possible management by optometrist

Advice (1) 

  • Reassure the patient that a pinguecula is a benign conjunctival degeneration and poses no threat to sight or general health 

  • Advise on measures to reduce ultraviolet exposure, including:  

    • Wrap‑around sunglasses 

    • A wide‑brimmed hat when outdoors  

  • During episodes of inflammation (pingueculitis), cold compresses may help alleviate symptoms  

Treatment

Symptomatic Pinguecula 

  • Ocular lubricants for symptomatic relief as required (drops/gel for use during the day ± unmedicated ointment for use at bedtime) (7). Refer to local formularies for suitable options (6) 

Note:  Patients on long‑term topical medication may develop sensitivity reactions to active agents or preservatives. Consider switching to preservative‑free  preparations as  required (1) 

Pingueculitis 

  • A short course of a mild topical corticosteroid (e.g. fluorometholone) may be considered (1)

  • A topical non‑steroidal anti‑inflammatory drug may be considered as an alternative (1)(e.g. ketorolac trometamol (7), off‑licence use (1)) 

Important: Monitor inflammatory response to steroid and measure IOP regularly during tapering schedule and on completion (1,7) 


Typical dosage/duration 

(Blue text = IP, black text = non-IP) 

  • Fluorometholone (FML) 0.1% eye drops (1,5) (POM): One drop (7), two to four times daily. For more serious conditions apply every (waking (7)) hour for 24-48 hours, then reduce to two to four times daily (2,3). Duration will depend on severity of the condition (6) 

  • Ketorolac trometamol 0.5% eye drops (1,6) (POM, off- label): One drop, three times daily for up to 3 weeks (2,3). 

Regimens should be adjusted according to severity and patient factors (e.g. age, weight, pregnancy, renal function). Prescribing should follow local formulary and national guidance where available (7).  

In cases of known sensitivities, please consult local formularies for alternative options (7). 


Further management options 

  • Treatment may be provided within available locally enhanced schemes, or by community IP optometrists/OMPs, as appropriate (7)

  • Normally no referral required (1)


Possible management in secondary care or local/community pathways where available 

  • See Further management options(7) 

  • Surgical intervention is rarely necessary (1)

  • In selected cases, usually for cosmetic reasons or persistent symptoms, options may include (1):  

    • Surgical excision 

    • Excision with conjunctival autografting 

    • Argon laser photocoagulation


College of Optometrists Clinical Management Guideline (1) 

Pinguecula - College of Optometrists * 

*With special thanks to The College of Optometrists for providing the evidence framework for diagnosis and management from the Clinical Management Guidelines (CMGs) for this condition. All references to the College/CMGs are included where appropriate and form the basis of the Community Eyecare Guidelines.


Guidance is informed by the following sources 

  1. College of Optometrists Clinical Management Guidelines Clinical Management Guidelines - College of Optometrists

  2. Advisory alignment with the College of Optometrists Formulary Optometrists' Formulary - College of Optometrists

  3. Advisory alignment with the BNF BNF (British National Formulary) | NICE

  4. Advisory alignment with the Summary Product Characteristics taken from the EMC Home - electronic medicines compendium (emc)

  5. Advisory alignment with Scottish Health Board formularies (where a clear majority is present) *

  6. Advisory alignment with expert consensus (CEGG), informed by sources 2-5 above

  7. Advisory alignment with expert consensus (CEGG) 

  8. “Annex C of the Statement” https://www.eyes.nhs.scot/for-professionals/legislation/

* Scottish formularies should be available within the Prescribing section of your Health Board pages on the eyes.nhs.scot website. If unavailable, contact your local Health Board for further information; Health Boards landing page


If you have a query relating to this page, please email NSS.ComEyecareGuidelineGroup@nhs.scot